November 8, 2024 11:08 AM EST
News Briefing

Dai­ichi, Al­teogen to work on sub­cu­ta­neous En­her­tu; Roche ends Nykode deal

ENDPOINTS

Plus, news about Disc Med­i­cine, AlloVir, Kalaris, Tra­vere Ther­a­peu­tics and Treve­na:

Dai­ichi Sankyo, Al­teogen to de­vel­op sub­cu­ta­neous ver­sion of En­her­tu: Dai­ichi will pay $20 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Leg­end names a pres­i­dent of Carvyk­ti; No­vo Nordisk's top North Amer­i­ca ex­ec is step­ping down

Charles Riv­er to close ‘15 small­er sites’ as de­mand for ear­ly re­search de­clines

Benev­o­len­tAI’s co-founder is back. Here’s how he plans a turn­around at the AI com­pa­ny dur­ing a ‘piv­otal time’

Athi­ra gives up on lead Alzheimer’s drug, switch­es tack to ALS

Nkar­ta drops an­oth­er can­cer pro­gram as it leans in­to au­toim­mune dis­ease

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times